Abstract:

Objective To investigate the distribution of hepatitis B virus (HBV) genotype of hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients treated by lamivudine and its relationship with the efficiency of antiviral therapy. Methods A total of 122 HBeAg positive CHB patients were genotyped and received lamivudine treatment for 1 year, and the relationships of HBV genotype with HBV DNA, HBeAg, alanine aminotransferase(ALT)and HBV P gene variation were analyzed. Results Among the 122 HBeAg positive CHB patients, there were 34 cases of B genotype (27. 87%), 82 cases of C genotype (67.21%), 3 cases of D genotype (2.45%), 1 case of C / D mixed genotype (0.82%) and 2 cases of B / C mixed genotype (1.64%).The turning negative rates of HBV DNA and HBeAg in CHB patients with genotype B were higher significantly than those with genotype C(P<0.01), and the HBV DNA level was lower significantly than that with genotype C (P<0.05). The rate of normalization ALT was higher than that with genotype C, but had no statistical significance (P>0.05). Genotype B group were mainly patients with mild CHB (44.12 %), while genotype C group were mainly patients with uncompensated liver cirrhosis (30.49%). Genotype B infection group had no gene variation, there were 4 cases of variation in genotype C infection group, and there was no statistical significance(P>0.05). Conclusions HBV genotype C of HBeAg positive CHB patients is the major genotype in Shaoxing. HBV patients with geotype B infection have better response for antiviral therapy than those with genotype C infection, and the clinical manifestation is light.

Key words: Genotype, Hepatitis B e antigen, Hepatitis B virus, Lamivudine